Distribution of Risk Factors in Ocular Hypertension and Open-Angle Glaucoma Patients in Canada

February 1, 2021 updated by: Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

Distribution of Risk Factors Amongst Ocular Hypertension and Open-Angle Glaucoma Patients in Canada

This descriptive, non-interventional study will collect information on the presence of risk factors in newly diagnosed ocular hypertension and open-angle glaucoma patients in Canada.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Study Type

Observational

Enrollment (Actual)

410

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Canada
    • Alberta
      • Calgary, Alberta, Canada, T3E 7M8
        • Pfizer Investigational Site
      • Edmonton, Alberta, Canada, T5H 3V9
        • Pfizer Investigational Site
      • Edmonton, Alberta, Canada, T5H 0X5
        • Pfizer Investigational Site
    • British Columbia
      • Nanaimo, British Columbia, Canada, V9R 5B6
        • Pfizer Investigational Site
      • Vancouver, British Columbia, Canada, V6K 1V7
        • Pfizer Investigational Site
      • Williams Lake, British Columbia, Canada, V2G 1H1
        • Pfizer Investigational Site
    • Manitoba
      • Winnipeg, Manitoba, Canada, R3C 0N2
        • Pfizer Investigational Site
    • Nova Scotia
      • Sydney, Nova Scotia, Canada, B1P 1P2
        • Pfizer Investigational Site
    • Ontario
      • Brampton, Ontario, Canada, L6V 1B4
        • Pfizer Investigational Site
      • Hamilton, Ontario, Canada, L8M 1L6
        • Pfizer Investigational Site
      • London, Ontario, Canada, N6A 4V2
        • Pfizer Investigational Site
      • Mississauga, Ontario, Canada, L5L 1W8
        • Pfizer Investigational Site
      • Oakville, Ontario, Canada, L6H 3P1
        • Pfizer Investigational Site
      • Oakville, Ontario, Canada, L6L 5G8
        • Pfizer Investigational Site
      • Toronto, Ontario, Canada, M4N 3M5
        • Pfizer Investigational Site
      • Toronto, Ontario, Canada, M5T 2S8
        • Pfizer Investigational Site
      • Toronto, Ontario, Canada, M5M 1B2
        • Pfizer Investigational Site
    • Quebec
      • Montreal, Quebec, Canada, H1T 2M4
        • Pfizer Investigational Site
      • Montreal, Quebec, Canada, H1V 1G5
        • Pfizer Investigational Site
      • Sherbrooke, Quebec, Canada, J1K 1EB
        • Pfizer Investigational Site
    • Saskatchewan
      • Saskatoon, Saskatchewan, Canada, S7K 3H3
        • Pfizer Investigational Site

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

Canadian population

Description

Inclusion Criteria:

  • Subjects diagnosed at study visit or within 3 months of visit with OH
  • OAG (to include POAG, NTG, pigmentary and pseudoexfoliation glaucoma)

Exclusion Criteria:

  • No prior treatment for OH or OAG
  • No prior ocular surgery or history of ocular trauma

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
There is no intervention in this study
This study is collecting information on the presence of risk factors in new diagnosed OH and OAG patients in Canada.
Other: There is no intervention in this study.
This study is collecting information on the presence of risk factors in new diagnosed OH and OAG patients in Canada.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
To describe the presence and distribution of risk factors in subjects diagnosed with OH or OAG stratified according to geographic distribution in a Canadian population in the ophthalmologist practice.
Time Frame: duration of study
duration of study

Secondary Outcome Measures

Outcome Measure
Time Frame
To describe the severity of disease at the time of diagnosis and to determine if there is a correlation between risk factors, or number of risk factors, and the severity of disease at presentation.
Time Frame: duration of study
duration of study

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Helpful Links

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

November 1, 2007

Primary Completion (Actual)

April 1, 2009

Study Completion (Actual)

April 1, 2009

Study Registration Dates

First Submitted

June 5, 2006

First Submitted That Met QC Criteria

June 5, 2006

First Posted (Estimate)

June 8, 2006

Study Record Updates

Last Update Posted (Actual)

February 2, 2021

Last Update Submitted That Met QC Criteria

February 1, 2021

Last Verified

September 1, 2010

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • A6111125

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Ocular Hypertension

Clinical Trials on There is no intervention in this study.

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Benin

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe